Effect of Long-Term Allopurinol Therapy on Left Ventricular Mass Index in Patients with Ischemic Heart Disease; A Cross-Sectional Study

References

• Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham Study. Ann Intern Med. 1970;72(6):813–822. doi:10.7326/0003-4819-72-6-8134247338
   PubMedGoogle Scholar
• Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561–1566. doi:10.1056/NEJM1990053132222032139921
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25(4):879–884. doi:10.1016/0735-1097(94)00473-47884091
   PubMed Web of Science ®Google Scholar
• Tsao CW, Gona PN, Salton CJ, et al. Left ventricular structure and risk of cardiovascular events: a Framingham heart study cardiac magnetic resonance study. J Am Heart Assoc. 2015;4(9):e002188. doi:10.1161/JAHA.115.00218826374295
   PubMed Web of Science ®Google Scholar
• Ang DS, Pringle SD, Struthers AD. The cardiovascular risk factor, left ventricular hypertrophy, is highly prevalent in stable, treated angina pectoris. Am J Hypertens. 2007;20(10):1029–1035. doi:10.1016/j.amjhyper.2007.04.02117903683
   PubMed Web of Science ®Google Scholar
• Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA. 1995;273(20):1592–1597. doi:10.1001/jama.1995.035204400460357745772
   PubMed Web of Science ®Google Scholar
• Ramirez AJ, Christen AI, Sanchez RA. Serum uric acid elevation is associated to arterial stiffness in hypertensive patients with metabolic disturbances. Curr Hypertens Rev. 2018;14(2):154–160. doi:10.2174/157340211466618041314331229651957
   PubMed Web of Science ®Google Scholar
• Chen HH, Sun YS, Liu ML. [Association between ambulatory arterial stiffness index with left ventricular mass index in the elderly hypertensive patients]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(9):750–753. doi:10.3760/cma.j.issn.0253-3758.2016.09.00427667271
   PubMedGoogle Scholar
• Ofori S, Akpa M. Relationship between uric acid and left ventricular mass and geometry in Nigerian patients with untreated essential hypertension. Niger J Cardiol. 2015;12(2):129–135. doi:10.4103/0189-7969.152024
   Google Scholar
• Matsumura K, Ohtsubo T, Oniki H, Fujii K, Iida M. Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension. Circ J. 2006;70(7):885–888. doi:10.1253/circj.70.88516799243
   PubMed Web of Science ®Google Scholar
• Catena C, Colussi G, Capobianco F, Brosolo G, Sechi LA. Uricaemia and left ventricular mass in hypertensive patients. Eur J Clin Invest. 2014;44(10):972–981. doi:10.1111/eci.1233125186106
   PubMed Web of Science ®Google Scholar
• Liu CW, Chen KH, Tseng CK, Chang WC, Wu YW, Hwang JJ. The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals. Nutr Metab Cardiovasc Dis. 2019;29(1):30–38. doi:10.1016/j.numecd.2018.10.00130545672
   PubMed Web of Science ®Google Scholar
• Mitsuhashi H, Yatsuya H, Matsushita K, et al. Uric acid and left ventricular hypertrophy in Japanese men. Circ J. 2009;73(4):667–672. doi:10.1253/circj.CJ-08-062619225200
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Facchetti R, Bombelli M, et al. Uric acid and new onset left ventricular hypertrophy: findings from the PAMELA population. Am J Hypertens. 2017;30(3):279–285. doi:10.1093/ajh/hpw15928096148
   PubMed Web of Science ®Google Scholar
• Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49(2):241–248. doi:10.1161/01.HYP.0000254415.31362.a717190878
   PubMed Web of Science ®Google Scholar
• Laakso JT, Teravainen TL, Martelin E, Vaskonen T, Lapatto R. Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens. 2004;22(7):1333–1340. doi:10.1097/01.hjh.0000125441.28861.9f15201549
   PubMed Web of Science ®Google Scholar
• Engberding N, Spiekermann S, Schaefer A, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation. 2004;110(15):2175–2179. doi:10.1161/01.CIR.0000144303.24894.1C15466649
   PubMed Web of Science ®Google Scholar
• Gao X, Xu Y, Xu B, et al. Allopurinol attenuates left ventricular dysfunction in rats with early stages of streptozotocin-induced diabetes. Diabetes Metab Res Rev. 2012;28(5):409–417. doi:10.1002/dmrr.229522389139
   PubMed Web of Science ®Google Scholar
• Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011;22(7):1382–1389. doi:10.1681/ASN.201011118521719783
   PubMed Web of Science ®Google Scholar
• Szwejkowski BR, Gandy SJ, Rekhraj S, et al. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol. 2013;62(24):2284–2293. doi:10.1016/j.jacc.2013.07.07423994420
   PubMed Web of Science ®Google Scholar
• Rekhraj S, Gandy SJ, Szwejkowski BR, et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61(9):926–932. doi:10.1016/j.jacc.2012.09.06623449426
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, von EE, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297. doi:10.1371/journal.pmed.004029717941715
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39. doi:10.1016/j.echo.2014.10.00325559473
   PubMed Web of Science ®Google Scholar
• Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol. 1984;4(6):1222–1230. doi:10.1016/S0735-1097(84)80141-26238987
   PubMed Web of Science ®Google Scholar
• Rosa EC, Moyses VA, Sesso RC, et al. Left ventricular hypertrophy evaluation in obese hypertensive patients: effect of left ventricular mass index criteria. Arq Bras Cardiol. 2002;78(4):341–351. doi:10.1590/S0066-782X200200040000112011950
   PubMedGoogle Scholar
• Cuspidi C, Meani S, Negri F, et al. Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives? J Hum Hypertens. 2009;23(11):728–734. doi:10.1038/jhh.2009.1619322202
   PubMed Web of Science ®Google Scholar
• Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension. 2002;39(3):750–755. doi:10.1161/hy0302.10467411897757
   PubMed Web of Science ®Google Scholar
• Gardin JM, Siscovick D, Anton-Culver H, et al. Sex, age, and disease affect echocardiographic left ventricular mass and systolic function in the free-living elderly. The Cardiovascular Health Study. Circulation. 1995;91(6):1739–1748.7882482
   PubMed Web of Science ®Google Scholar
• Gosse P. Left ventricular hypertrophy–the problem and possible solutions. J Int Med Res. 2005;33 Suppl 1:3A–11A. doi:10.1177/14732300050330S102
   PubMed Web of Science ®Google Scholar
• Brunner D JM, Schreiner PJ, Xie X, et al. Demographics and correlates of five-year change in echocardiographic left ventricular mass in young black and white adult men and women: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Am Coll Cardiol. 2002;40(3):529–535. doi:10.1016/S0735-1097(02)01973-312142122
   PubMed Web of Science ®Google Scholar
• Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27(3):347–354. doi:10.1016/S0272-6386(96)90357-18604703
   PubMed Web of Science ®Google Scholar
• Armstrong AC, Gidding S, Gjesdal O, Wu C, Bluemke DA, Lima JA. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging. 2012;5(8):837–848. doi:10.1016/j.jcmg.2012.06.00322897998
   PubMed Web of Science ®Google Scholar
• Reichek N. Left ventricular hypertrophy regression and allopurinol: more questions than answers. J Am Coll Cardiol. 2013;62(24):2294–2296. doi:10.1016/j.jacc.2013.08.69523994396
   PubMed Web of Science ®Google Scholar
• Mark PB, Johnston N, Groenning BA, et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int. 2006;69(10):1839–1845. doi:10.1038/sj.ki.500024916508657
   PubMed Web of Science ®Google Scholar
• Choi HK, Soriano LC, Zhang Y, Rodriguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;12(344):d8190. doi:10.1136/bmj.d8190
   Google Scholar
• Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15(6):435–442. doi:10.1111/j.1751-7176.2012.00701.x23730993
   PubMed Web of Science ®Google Scholar
• Shelmadine B, Bowden RG, Wilson RL, Beavers D, Hartman J. The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study. Anadolu Kardiyol Derg. 2009;9(5):385–389.19819789
   PubMedGoogle Scholar
• Bowden RG, Shelmadine BD, Moreillon JJ, Deike E, Griggs JO, Wilson RL. Effects of uric acid on lipid levels in CKD patients in a randomized controlled trial. Cardiol Res. 2013;Apr(2):56–63.
   Google Scholar
• Sato H, Carvalho G, Sato T, et al. Statin intake is associated with decreased insulin sensitivity during cardiac surgery. Diabetes Care. 2012;35(10):2095–2099. doi:10.2337/dc11-225122829524
   PubMed Web of Science ®Google Scholar
• Kain V, Kapadia B, Misra P, Saxena U. Simvastatin may induce insulin resistance through a novel fatty acid mediated cholesterol independent mechanism. Sci Rep. 2015;8(5):13823. doi:10.1038/srep13823
   Google Scholar
• Schliess F, von DS, Haussinger D. Insulin resistance induced by loop diuretics and hyperosmolarity in perfused rat liver. Biol Chem. 2001;382(7):1063–1069. doi:10.1515/BC.2001.13311530937
   PubMed Web of Science ®Google Scholar
• Dimitriadis G, Leighton B, Parry-Billings M, Tountas C, Raptis S, Newsholme EA. Furosemide decreases the sensitivity of glucose transport to insulin in skeletal muscle in vitro. Eur J Endocrinol. 1998;139(1):118–122. doi:10.1530/eje.0.13901189703388
   PubMed Web of Science ®Google Scholar
• Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001;322(7277):15–18. doi:10.1136/bmj.322.7277.1511141143
   PubMed Web of Science ®Google Scholar
• Liu P, Wang H, Zhang F, Chen Y, Wang D, Wang Y. The effects of allopurinol on the carotid intima-media thickness in patients with type 2 diabetes and asymptomatic hyperuricemia: a three-year randomized parallel-controlled study. Intern Med. 2015;54(17):2129–2137. doi:10.2169/internalmedicine.54.431026328636
   PubMed Web of Science ®Google Scholar
• Takir M, Kostek O, Ozkok A, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63(8):924–929. doi:10.1097/JIM.0000000000000242
   PubMed Web of Science ®Google Scholar
• Fujimura Y, Yamauchi Y, Murase T, et al. Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients. PLoS One. 2017;12(8):e0182699. doi:10.1371/journal.pone.018269928797123
   PubMed Web of Science ®Google Scholar
• El-Bassossy HM, Elberry AA, Azhar A, Ghareib SA, Alahdal AM. Ameliorative effect of allopurinol on vascular complications of insulin resistance. J Diabetes Res. 2015;2015:178540. doi:10.1155/2015/17854025785277
   PubMed Web of Science ®Google Scholar
• Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS One. 2012;7(10):e47948. doi:10.1371/journal.pone.004794823112875
   PubMed Web of Science ®Google Scholar
• Xu C, Lin Y, Lu C, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64(4):925–932. doi:10.1016/j.jhep.2015.11.02226639394
   PubMed Web of Science ®Google Scholar
• Choi YJ, Yoon Y, Lee KY, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 2014;28(7):3197–3204. doi:10.1096/fj.13-24714824652948
   PubMed Web of Science ®Google Scholar
• George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508–2516. doi:10.1161/CIRCULATIONAHA.106.65111717130343
   PubMed Web of Science ®Google Scholar
• Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161–2167. doi:10.1016/S0140-6736(10)60391-120542554
   PubMed Web of Science ®Google Scholar
• Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) Study. Circulation. 2015;131(20):1763–1771. doi:10.1161/CIRCULATIONAHA.114.01453625986447
   PubMed Web of Science ®Google Scholar
• Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM. Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol. 2011;71(4):600–607. doi:10.1111/bcp.2011.71.issue-421395653
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Gil MJ, Rodriguez A, et al. Allopurinol use and risk of non-fatal acute myocardial infarction. Heart. 2015;101(9):679–685. doi:10.1136/heartjnl-2014-30667025561685
   PubMed Web of Science ®Google Scholar
• Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart. 2002;87(3):229–234. doi:10.1136/heart.87.3.22911847159
   PubMed Web of Science ®Google Scholar
• Alem MM. Allopurinol and endothelial function: a systematic review with meta-analysis of randomized controlled trials. Cardiovasc Ther. 2018;36(4):e12432. doi:10.1111/cdr.2018.36.issue-429673103
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–1393. doi:10.2215/CJN.0158021020538833
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Garcia V, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis. 2015;65(4):543–549. doi:10.1053/j.ajkd.2014.11.01625595565
   PubMed Web of Science ®Google Scholar